A nationwide cohort study examines the oncologic safety of GLP-1 receptor agonists in patients with endogenous Cushing syndrome.
Sleeve gastrectomy may offer greater weight loss and glycemic control than semaglutide or tirzepatide in adults with obesity and T2D.